Medicine and Dentistry
Melanoma
100%
Neoplasm
63%
Colorectal Carcinoma
60%
Breast Cancer
38%
Sentinel Node
36%
Diseases
34%
Recurrent Disease
32%
Sentinel Lymph Node
30%
Lymph Node
28%
Metastatic Carcinoma
27%
Retroperitoneal Lymph Node Dissection
26%
Sentinel Lymph Node Biopsy
26%
Biopsy Technique
17%
Monoclonal Antibody
16%
Carcinoembryonic Antigen
15%
Iodine 125
14%
Surgeon
14%
Mitomycin
13%
Monoclonal Antibody CC49
12%
Technetium-99
12%
Malignant Neoplasm
12%
Quadrantectomy
12%
Tumor Infiltrating Lymphocyte
12%
Overall Survival
11%
Lymphoscintigraphy
11%
Sentinel-Node Mapping
11%
Sentinel Lymph Node Metastasis
11%
Hazard Ratio
10%
Lymph Node Metastasis
10%
Melanoma Skin Cancer
9%
Carcinomatous Peritonitis
9%
Magnetic Resonance Imaging
8%
Single Photon Emission Computed Tomography-Computed Tomography
8%
Haematoxylin
7%
Colon Carcinoma
7%
Eosin
7%
Venous Ulcer
7%
Scintigraphy
7%
Neck
7%
Lumpectomy
6%
Squamous Cell Carcinoma
6%
Liver Metastasis
6%
Recurrence Risk
6%
Peritoneum Metastasis
6%
Radioisotope
6%
Mastectomy
6%
Surgical Exploration
6%
Primary Tumor
5%
Disease Free Survival
5%
Metastatic Melanoma
5%
Keyphrases
Melanoma
67%
Sentinel Lymph Node Biopsy
36%
Sentinel Lymph Node
36%
Monoclonal Antibody
33%
Tumor
32%
CC49
30%
Colorectal Cancer
26%
Recurrent Colorectal Cancer
25%
Sentinel Lymph Node Mapping
24%
Detecting Probe
21%
Melanoma-specific Survival
20%
Breast Cancer
19%
Lymph Node
18%
Melanoma Patients
15%
Confidence Interval
15%
Radiolabeled Antibody
14%
125I
13%
Breast Reconstruction
13%
Breast Cancer Patients
13%
Surgeons
13%
Intraperitoneal Hyperthermic Perfusion
12%
Thick Melanoma
12%
International Society
12%
Tumor-infiltrating Lymphocytes
12%
Hazard Ratio
12%
Lymphoscintigraphy
12%
Colorectal Carcinoma
11%
Overall Survival
11%
Sentinel Lymph Node Metastasis
11%
Blue Dye
10%
Carcinoembryonic Antigen
10%
Metastasis
10%
Handheld
10%
Disease-free Survival
9%
Lymph Node Dissection
9%
Tumor Site
9%
Completion Lymph Node Dissection
9%
Sentinel Node Metastasis
9%
Lymph Node Metastasis
9%
Peritoneal Carcinomatosis
9%
Metastatic Melanoma
9%
Mitomycin C
9%
Recurrence Rate
8%
Node-positive
8%
Occult
8%
Carcinoembryonic Antigen Levels
8%
SPECT-CT
8%
Phase II Trial
8%
CT System
8%
Tilmanocept
8%